Smart socks assist in diagnosis, treatment of injuries in remote patients

A new type of "smart" socks could improve the diagnosis and treatment of remote patients by providing physiotherapists with real-time information on lower body movements.

“What was lacking in video consultations was the ability to observe the subtle differences in patients’ lower limb movements, such as shifts in weight distribution and range of foot movements,” said developer and University of Melbourne PhD candidate Deepti Aggarwal. “This meant that physiotherapists had limited understanding of the patient’s actual recovery, leading to less specific treatment. The physiotherapists were also reluctant to try out new exercises with the patients over video.”

The SoPhy system consists of a pair of socks with three sensors that capture data on a patient’s lower body movement through weight distribution, range of movement and foot orientation. The collected data then provide physiotherapists a web-interface view on movement.

“Often, without realizing it, patients will apply different tricks to not bear weight on the injured leg, such as pushing through their toes or heels,” said Aggarwal. “These movements are so subtle that they can be missed by the naked eye, even in a face-to-face consultation. The SoPhy visualization clearly highlights whether the patient is bearing any weight on the injured leg and in which parts, such as in the front, side or on the heels of the foot.”

Read the full story below:

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.